Craig Logsdon
Overview
Explore the profile of Craig Logsdon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng L, Zhuang L, Lin K, Yao Y, Zhang Y, Arumugam T, et al.
Pancreatology
. 2020 Dec;
21(1):115-123.
PMID: 33341341
Glutathione-S-transferases (GSTs) not only show cytoprotective role and their involvement in the development of anticancer drug resistance, but also transmit signals that control cell proliferation and apoptosis. However, the role...
2.
Sutton M, Lu Z, Li Y, Zhou Y, Huang T, Reger A, et al.
Cell Rep
. 2019 Dec;
29(11):3448-3459.e6.
PMID: 31825828
Oncogenic RAS mutations drive cancers at many sites. Recent reports suggest that RAS dimerization, multimerization, and clustering correlate strongly with activation of RAS signaling. We have found that re-expression of...
3.
Cocce K, Jasper J, Desautels T, Everett L, Wardell S, Westerling T, et al.
Cell Rep
. 2019 Oct;
29(4):889-903.e10.
PMID: 31644911
Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that...
4.
Abbruzzese J, Andersen D, Borrebaeck C, Chari S, Costello E, Cruz-Monserrate Z, et al.
Pancreas
. 2018 Apr;
47(5):516-525.
PMID: 29702529
A workshop on "The Interface of Pancreatic Cancer with Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities" was held by the National Institute of Diabetes and Digestive and Kidney Diseases...
5.
Chen L, Duan Z, Tinker L, Sangi-Haghpeykar H, Strickler H, Ho G, et al.
Cancer Epidemiol
. 2016 Apr;
42:115-23.
PMID: 27100837
Objectives: Receptor for advanced glycation end products (RAGE) expressed on adipocytes and immune cells can bind to ligand N(ε)-(carboxymethyl)-lysine (CML) and trigger dysregulation of adipokines and chronic inflammation. Soluble RAGE...
6.
Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, et al.
Mol Cancer Ther
. 2014 Sep;
13(11):2583-94.
PMID: 25193509
Pancreatic stellate cells (PSC) have been recognized as the principal cells responsible for the production of fibrosis in pancreatic ductal adenocarcinoma (PDAC). Recently, PSCs have been noted to share characteristics...
7.
Wang H, Chen Y, Lin P, Li L, Zhou G, Liu G, et al.
J Biol Chem
. 2013 Dec;
289(7):4009-17.
PMID: 24362026
HPK1, a member of mammalian Ste20-like serine/threonine kinases, is lost in >95% pancreatic cancer through proteasome-mediated degradation. However, the mechanism of HPK1 loss has not been defined. The aims of...
8.
Song S, Ji B, Ramachandran V, Wang H, Hafley M, Logsdon C, et al.
PLoS One
. 2012 Aug;
7(8):e42699.
PMID: 22900040
Pancreatic cancer (PDAC) is a lethal disease with a five-year survival of 3-5%. Mutations in K-Ras are found in nearly all cases, but K-Ras mutations alone are not sufficient for...
9.
Chang D, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese J, et al.
J Hematol Oncol
. 2012 Apr;
5:15.
PMID: 22475564
Purpose: Cell division cycle 20 (CDC20) homolog is an anaphase-promoting complex activator that is essential for cell division, but whether its expression in pancreatic ductal adenocarcinoma (PDAC) is significant is...
10.
Kim M, Truty M, Choi W, Kang Y, Chopin-Lally X, Gallick G, et al.
Ann Surg Oncol
. 2011 Jun;
19 Suppl 3:S395-403.
PMID: 21701930
Background: Pancreatic adenocarcinoma is among the most resistant of human cancers, yet specific mechanisms of treatment resistance remain poorly understood. Models to study pancreatic cancer resistance remain limited and should...